Targeted screening and identification of chlorhexidine as a pro-myogenic circadian clock activator.

Circadian clock Drug screening Muscle stem cell Myoblast differentiation Myogenesis Myogenic progenitor Small molecule

Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
31 07 2023
Historique:
received: 28 09 2022
accepted: 21 07 2023
medline: 3 8 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: epublish

Résumé

The circadian clock is an evolutionarily conserved mechanism that exerts pervasive temporal control in stem cell behavior. This time-keeping machinery is required for orchestrating myogenic progenitor properties in regenerative myogenesis that ameliorates muscular dystrophy. Here we report a screening platform to discover circadian clock modulators that promote myogenesis and identify chlorhexidine (CHX) as a clock-activating molecule with pro-myogenic activities. A high-throughput molecular docking pipeline was applied to identify compounds with a structural fit for a hydrophobic pocket within the key circadian transcription factor protein, Circadian Locomotor Output Cycles Kaput (CLOCK). These identified molecules were further screened for clock-modulatory activities and functional validations for pro-myogenic properties. CHX was identified as a clock activator that promotes distinct aspects of myogenesis. CHX activated circadian clock that reduced cycling period length and augmented amplitude. This action was mediated by the targeted CLOCK structure via augmented interaction with heterodimer partner Bmal1, leading to enhanced CLOCK/Bmal1-controlled transcription with upregulation of core clock genes. Consistent with its clock-activating function, CHX displayed robust effects on stimulating myogenic differentiation in a clock-dependent manner. In addition, CHX augmented the proliferative and migratory activities of myoblasts. Our findings demonstrate the feasibility of a screening platform to discover clock modulators with myogenic regulatory activities. Discovery of CHX as a pro-myogenic molecule could be applicable to promote regenerative capacities in ameliorating dystrophic or degenerative muscle diseases.

Sections du résumé

BACKGROUND
The circadian clock is an evolutionarily conserved mechanism that exerts pervasive temporal control in stem cell behavior. This time-keeping machinery is required for orchestrating myogenic progenitor properties in regenerative myogenesis that ameliorates muscular dystrophy. Here we report a screening platform to discover circadian clock modulators that promote myogenesis and identify chlorhexidine (CHX) as a clock-activating molecule with pro-myogenic activities.
METHODS
A high-throughput molecular docking pipeline was applied to identify compounds with a structural fit for a hydrophobic pocket within the key circadian transcription factor protein, Circadian Locomotor Output Cycles Kaput (CLOCK). These identified molecules were further screened for clock-modulatory activities and functional validations for pro-myogenic properties.
RESULTS
CHX was identified as a clock activator that promotes distinct aspects of myogenesis. CHX activated circadian clock that reduced cycling period length and augmented amplitude. This action was mediated by the targeted CLOCK structure via augmented interaction with heterodimer partner Bmal1, leading to enhanced CLOCK/Bmal1-controlled transcription with upregulation of core clock genes. Consistent with its clock-activating function, CHX displayed robust effects on stimulating myogenic differentiation in a clock-dependent manner. In addition, CHX augmented the proliferative and migratory activities of myoblasts.
CONCLUSION
Our findings demonstrate the feasibility of a screening platform to discover clock modulators with myogenic regulatory activities. Discovery of CHX as a pro-myogenic molecule could be applicable to promote regenerative capacities in ameliorating dystrophic or degenerative muscle diseases.

Identifiants

pubmed: 37525228
doi: 10.1186/s13287-023-03424-2
pii: 10.1186/s13287-023-03424-2
pmc: PMC10391781
doi:

Substances chimiques

Chlorhexidine R4KO0DY52L
ARNTL Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

190

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK112794
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Nat Chem Biol. 2020 Jun;16(6):676-685
pubmed: 32231341
Science. 2012 Jul 13;337(6091):189-94
pubmed: 22653727
J Intern Med. 2015 May;277(5):513-27
pubmed: 25599827
Nat Rev Endocrinol. 2019 Feb;15(2):75-89
pubmed: 30531917
FASEB J. 2012 Aug;26(8):3453-63
pubmed: 22611086
Science. 2021 Jan 1;371(6524):
pubmed: 33384351
Exp Cell Res. 2021 Sep 15;406(2):112766
pubmed: 34364881
Exp Cell Res. 2020 Dec 1;397(1):112348
pubmed: 33130178
J Cell Sci. 2013 May 15;126(Pt 10):2213-24
pubmed: 23525013
J Med Chem. 2004 Mar 25;47(7):1750-9
pubmed: 15027866
Cell. 2017 Aug 10;170(4):678-692.e20
pubmed: 28802040
J Med Chem. 2010 Apr 8;53(7):2719-40
pubmed: 20131845
Cancer Discov. 2019 Nov;9(11):1556-1573
pubmed: 31455674
Science. 2010 Dec 3;330(6009):1349-54
pubmed: 21127246
Cell. 2002 Jul 26;110(2):251-60
pubmed: 12150932
Nat Commun. 2019 Aug 28;10(1):3923
pubmed: 31462679
Anaesth Intensive Care. 2008 Jul;36(4):502-12
pubmed: 18714617
PLoS One. 2009 Aug 31;4(8):e6843
pubmed: 19718444
Nature. 2012 Mar 29;485(7396):62-8
pubmed: 22460951
FASEB J. 2020 May;34(5):6613-6627
pubmed: 32212194
Drug Discov Today Technol. 2004 Dec;1(4):337-41
pubmed: 24981612
Nature. 2018 Jan 18;553(7688):351-355
pubmed: 29320480
Nature. 2011 Apr 28;472(7344):491-4
pubmed: 21499262
Cell Metab. 2019 Jul 2;30(1):92-110.e4
pubmed: 31006592
Trends Cancer. 2019 Aug;5(8):475-494
pubmed: 31421905
Science. 2012 Aug 31;337(6098):1094-7
pubmed: 22798407
F1000Res. 2016 Jun 30;5:1549
pubmed: 27540471
J Cell Biol. 2021 Jul 5;220(7):
pubmed: 34009269
Nat Rev Drug Discov. 2014 Mar;13(3):197-216
pubmed: 24577401
Prog Mol Biol Transl Sci. 2013;119:221-82
pubmed: 23899600
PLoS Genet. 2008 Feb 29;4(2):e1000023
pubmed: 18454201
Trends Mol Med. 2008 Feb;14(2):82-91
pubmed: 18218339
Front Neurol. 2017 Mar 15;8:100
pubmed: 28360884
ACS Chem Biol. 2011 Feb 18;6(2):131-4
pubmed: 21043485
ChemMedChem. 2015 Sep;10(9):1489-97
pubmed: 26174033
Curr Drug Metab. 2016;17(5):503-12
pubmed: 26750111
EBioMedicine. 2016 Apr;6:73-86
pubmed: 27211550
J Dent. 2007 May;35(5):359-70
pubmed: 17391828
Physiol Rev. 2004 Jan;84(1):209-38
pubmed: 14715915
Sci Rep. 2017 Dec 7;7(1):17142
pubmed: 29215066
Exp Cell Res. 2015 Feb 1;331(1):200-210
pubmed: 25218946
Oncogene. 2021 May;40(18):3187-3200
pubmed: 33846572
J Am Chem Soc. 2005 Jan 12;127(1):217-24
pubmed: 15631471
Mol Cell Endocrinol. 2021 Feb 5;521:111110
pubmed: 33285245
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5339-46
pubmed: 14963227
Cold Spring Harb Symp Quant Biol. 2008;73:323-31
pubmed: 19329572
Cell Metab. 2016 Apr 12;23(4):610-21
pubmed: 27076076
Sci Rep. 2019 Mar 14;9(1):4585
pubmed: 30872796
Cell. 2002 May 3;109(3):307-20
pubmed: 12015981
Nature. 2011 Nov 09;480(7376):209-14
pubmed: 22080954
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19090-5
pubmed: 20956306
Nat Rev Genet. 2017 Mar;18(3):164-179
pubmed: 27990019
Trends Cell Biol. 2014 Feb;24(2):90-9
pubmed: 23916625
Cancer Cell. 2020 Jul 13;38(1):79-96.e11
pubmed: 32531268
F1000Res. 2017 Oct 30;6:1910
pubmed: 29152229
Science. 2016 Nov 25;354(6315):1008-1015
pubmed: 27885007
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):101-6
pubmed: 22184224
Cell Metab. 2012 Jun 6;15(6):791-3
pubmed: 22682217
Cell Stem Cell. 2013 Dec 5;13(6):745-53
pubmed: 24120744
Cell Stem Cell. 2020 Jun 4;26(6):817-831
pubmed: 32502402
Trends Pharmacol Sci. 2018 Sep;39(9):812-827
pubmed: 30060890
Cell Rep. 2018 Feb 20;22(8):2118-2132
pubmed: 29466738
J Oral Sci. 2020 Mar 28;62(2):202-205
pubmed: 32161233
Mol Metab. 2022 Jul;61:101504
pubmed: 35470095
Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2608-13
pubmed: 15699353
PLoS Genet. 2018 May 11;14(5):e1007369
pubmed: 29750810

Auteurs

Tali Kiperman (T)

Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.

Weini Li (W)

Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.

Xuekai Xiong (X)

Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.

Hongzhi Li (H)

Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.

David Horne (D)

Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.

Ke Ma (K)

Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA. kema@coh.org.

Articles similaires

Animals Hemiptera Insect Proteins Phylogeny Insecticides
Humans Circadian Rhythm Adult Aged Aging
Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics

Classifications MeSH